Niusule Biotech Corp., a fast-growing, China-based bio-pharmaceutical company focusing on animal-health products and human nutraceutical supplements, has announced its China-based subsidiary Tianjin Behigh Pharmaceutical Co., Ltd received 95.4 points (out of 100) on its Good Manufacturing Practices re-inspection from the Ministry of Agriculture of the People's Republic of China. The re-inspection, conducted May 29–30, 2010, is in accordance with the Ministry's required five-year re-evaluation to ensure that facilities servicing the Chinese agricultural community continue to adhere to government standards. The inspection enables Niusule to continue holding its existing operations certificate.
During the inspection, several aspects were assessed including: line production, laboratory safety, production control, inventory logistics on over 100 products, upkeep of the physical property, and proper management. All areas exceeded the Ministry's standards.
"Niusule is proud of our management and operations. Our dedication to the health, safety, and welfare of our facilities, employees, and customers is ingrained in our corporate culture. Having our internal standards measured and recognized by the Chinese Ministry of Agriculture validates our efforts and confirms that our corporate practices are of the highest caliber," stated Ms. Amy Hu, President and CEO of Niusule.
"Given the recent acquisition of Tianjin Behigh and our strong focus on offering premium animal health products to the Chinese agricultural community, the Ministry's positive inspection confirms that our plant runs safely and efficiently. We will continue on this path going forward, particularly as we look to expand our facilities at a future date. On the sales side, the GMP's positive inspection provides enhanced credibility as we market our products to new and existing clients as well as further expand our sales and distribution footprint across China," concluded Ms. Hu.
About Niusule Biotech, Inc.
Niusule Biotech Corp. is a bio-pharmaceutical company dedicated to offering high-quality pharmaceutical and nutritional supplement products to enhance both animal and human health. The Company has recently acquired a majority interest in Tianjin Behigh Pharmaceutical Co., Ltd, a veterinary drug and feed additives manufacturing company that produces injections, tablets, granules, oral solutions, powder and disinfectant for animal use. For the human product line, Niusule currently has a retail distribution network throughout China comprised of 124 outlets at high-end supermarkets and shopping malls in Zhejiang province, Shanghai and Beijing. For more information about Niusule Biotech Corp., please visit www.niusule.com.
Forward Looking Statements This news release contains certain "forward-looking statements." Forward-looking statements are based on current expectations and assumptions and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and many of which are beyond the Company's control. The forward-looking statements are also identified through the use of words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict" "probable," "potential," "possible," "should," "continue," "project," "expect" and other words of similar meaning. Actual results could differ materially from these forward-looking statements as a result of a number of risk factors detailed in the Company's periodic reports filed with the SEC. Given these risks and uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements and no assurances can be given that such statements will be achieved. Niusule Biotech Corp. does not assume any duty to publicly update or revise the material contained herein.